Mina Adel Nagi on the Future of ESR Testing with HORIBA’s CoRA Technology
Mina Adel Nagi, North and West Delta Regional Manager at Misreya Medical, shared on LinkedIn:
”Discover the Future of ESR Testing with Horiba ’s Patented CoRA Technology
For over 100 years, ESR (Erythrocyte Sedimentation Rate) has remained a key lab marker supporting the assessment of inflammation
Yet, the traditional Westergren approach is often manual, time-consuming, and disconnected from routine CBC workflows.
HORIBA’s CoRA (Correlated Rouleaux Analysis) changes the game by integrating ESR directly into automated hematology analyzers (Yumizen H500E and H550E)—turning a century-old test into a modern, streamlined solution.
The real shift: from “sedimentation” to “aggregation”
Instead of waiting for RBCs to sediment for an hour, CoRA focuses on the earliest ESR phase: rouleaux (RBC aggregation) formation, then correlates it to an ESR-equivalent value.
How it works (in 3 steps)
1. Aspiration / Suction
Whole blood is aspirated through an optical pathway; shear forces slightly deform RBCs, changing the optical signal.
2. Relaxation / Release
Aspiration pauses—cells recover their shape and optical behavior shifts again.
3.Agglomeration / Re-formation
RBCs form rouleaux; increasing intercellular spaces allow higher light transmission.
Near-infrared optical signals are analyzed to calculate ESR rapidly and reliably.
Protein effect
Inflammation increases plasma proteins (acute-phase proteins and immunoglobulins), reducing RBC repulsion → enhancing rouleaux formation → increasing ESR.
Why CoRA Matters
Patent-protected innovation: dynamic RBC aggregation analysis correlated to Westergren
Faster workflows: ESR + CBC/Diff in ~60 seconds
Added clinical value: faster inflammation assessment in critical care, infections, autoimmune cases
Space and cost optimization: one platform, fewer steps, fewer instruments
CoRA isn’t just an upgrade—it’s a paradigm shift, bringing a century-old gold standard into the automated era.”
Stay updated with Hemostasis Today.
-
Mar 15, 2026, 15:55Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 2
-
Mar 15, 2026, 14:09Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope
-
Mar 15, 2026, 14:02Denise M: Precision Hemostasis in Patient Blood Management
-
Mar 15, 2026, 13:57Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
-
Mar 15, 2026, 13:52Valentin Ortiz-Maldonado: High-Impact Innovation in CAR-T Therapy Can Emerge From Academic Programmes
-
Mar 15, 2026, 13:45Tareq Abadl: Has Anyone Here Ever Taken an ALP Test Before?
-
Mar 14, 2026, 21:30Ayman Elbadawi: Why Does Stent Thrombosis Still Occur? Insights from the NCDR Data
-
Mar 14, 2026, 20:03Edward Adomako: Recognizing Thrombotic Thrombocytopenic Purpura as A Life-Threatening Emergency
-
Mar 14, 2026, 19:28Vishnu Priya Pulipati: Statins Beyond Cholesterol for Plaque Biology and Cardiovascular Risk Reduction